Thimerosal (THI) is used as a preservative in many vaccines throughout the world. Ethylmercury (EtHg(+)), released from THI in aqueous media, has a high affinity to thiol functions of proteins. In blood, hemoglobin is a likely target protein because of its high abundance and its several free thiol functions. In comparison to hemoglobin of human origin, hemoglobin of rats exhibits almost twice as many free thiol groups, which might lead to different binding behavior and therefore a limited comparability between the situation in man and in rats, which are frequently used as models for mercury species toxicity investigations. Thus, the adduct formation of EtHg(+) with hemoglobin of humans and rats was compared under simulated physiological conditions by using gradient reversed-phase liquid chromatography (LC) with electrospray time-of-flight mass spectrometry (ESI-TOF-MS) detection. The binding stoichiometry correlated with the number of free thiols in the α- and β-chain of hemoglobin. The use of rats to verify the safety of additives in vaccines like Thimerosal is therefore doubtful and should be reevaluated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c1mt00043h | DOI Listing |
J Agric Food Chem
January 2025
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China.
Methyleugenol (ME) has been classified as a "group 2B carcinogen" by IARC. Its positional isomer methylisoeugenol (MIE) has been considered to be of "generally recognized as safe'' status by FDA. ME was more cytotoxic than MIE in cultured mouse primary hepatocytes.
View Article and Find Full Text PDFJ Phys Chem A
January 2025
Centro de Bioinformática, Simulación y Modelado (CBSM), Departamento de Bioinformática, Facultad de Ingeniería, Universidad de Talca, Talca 3465548, Chile.
In this research, we investigated the essential role of biogenic volatile organic compound emissions in regulating tropospheric ozone levels, atmospheric chemistry, and climate dynamics. We explored linalool ozonolysis and secondary organic aerosol formation mechanisms, providing key insights into atmospheric processes. Computational techniques, such as density functional theory calculations and molecular dynamics simulations, were employed for the analysis.
View Article and Find Full Text PDFInorg Chem
January 2025
Department of Chemistry, University of Calgary, 2500 University Dr. NW, T2N 1N4 Calgary, AB Canada.
The extent of coordination-induced bond weakening in aquo and hydroxo ligands bonded to a molybdenum(III) center complexed by a dianionic, pentadentate ligand system was probed by reacting the known complex (BPzPy)Mo(III)-NTf, , with degassed water or dry lithium hydroxide. The aquo adduct was not observed, but two LiNTf-stabilized hydroxo complexes were fully characterized. Computational and experimental work showed that the O-H bond in these complexes was significantly weakened (to ≈57 kcal mol), such that these compounds could be used to form the diamagnetic, neutral terminal molybdenum oxo complex (BPzPy)Mo(IV)O, , by hydrogen atom abstraction using the aryl oxyl reagent ArO• (Ar = 2,4,6-tri--butylphenyl).
View Article and Find Full Text PDFJ Chem Inf Model
January 2025
Medicinal Chemistry and Drug Design Technologies Department, Chiesi Farmaceutici S.p.A., Largo F. Belloli 11/A, 43122 Parma, Italy.
Janus kinase type 3 (JAK3), an emerging target for treating autoimmune diseases, possesses a front pocket cysteine that is targeted by covalent modifiers, best represented by the marketed drug ritlecitinib (). Recently, 2,3-dihydro-1-inden-1-ylcyanamides have been developed as novel JAK3 inhibitors. Among them, the -(6-(7-pyrrolo[2,3-]pyrimidin-4-yl)-2,3-dihydro-1-inden-1-yl)cyanamide inhibitor () and its methylated analogue (), while being potent inhibitors, displayed different mechanisms of action (covalent vs noncovalent) and binding modes (Casimiro-Garcia et al.
View Article and Find Full Text PDFACS Pharmacol Transl Sci
January 2025
Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Blvd, South San Francisco, California 94080, United States.
Antibody-drug conjugates (ADCs) are a promising drug modality substantially expanding in both the discovery space and clinical development. Assessing the biotransformation of ADCs and is important in understanding their stability and pharmacokinetic properties. We previously reported biotransformation pathways for the anti-B7H4 topoisomerase I inhibitor ADC, AZD8205, puxitatug samrotecan, that underpin its structural stability using an intact protein liquid chromatography-high resolution mass spectrometry (LC-HRMS) approach.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!